Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 2,339 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

NCT01656018
View directory record Official record
Conditions
Healthy
Interventions
TMC278, Long acting (LA)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332
View directory record Official record
Conditions
Type II Diabetes
Interventions
Placebo, Sitagliptin, LEZ763
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 17, 2026, 11:03 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)

NCT00779480
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML)
Interventions
KW-2449
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

NCT05813717
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986325, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3561774 in Participants With Dyslipidemia

NCT04644809
View directory record Official record
Conditions
Dyslipidemias
Interventions
LY3561774, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
5
States / cities
Cypress, California • Long Beach, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 17, 2026, 11:03 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

NCT07082829
View directory record Official record
Conditions
Excessive Daytime Sleepiness
Interventions
ORX142 Tablets, Placebo Tablets
Drug · Other
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Lincoln, Nebraska • Eatontown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

NCT00271765
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
INO-1001
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
10
States / cities
Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2006 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

NCT05723692
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ALTB-268, Placebo
Biological · Other
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT04143802
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3437943, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

NCT00657007
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab, Placebo
Biological
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers

NCT00820092
View directory record Official record
Conditions
Edema
Interventions
Xerecept 1.0, Xerecept 2.0, Xerecept 3.0
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
20 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

NCT02654002
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants

NCT04729101
View directory record Official record
Conditions
Healthy Participants
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apixaban in Nephrotic Syndrome

NCT02599532
View directory record Official record
Conditions
Nephrotic Syndrome, Proteinuria
Interventions
apixaban
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 79 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 17, 2026, 11:03 AM EDT
Recruiting Phase 1 Interventional

Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors

NCT06770764
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
ODC-IL2
Drug
Lead sponsor
Trutino Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 17, 2026, 11:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of ONO-7475 in Patients With Acute Leukemias

NCT03176277
View directory record Official record
Conditions
Acute Leukemia, Myelodysplastic Syndromes
Interventions
ONO-7475 3mg once daily, ONO-7475 6mg once daily, ONO-7475 10mg once daily, ONO-7475 6mg + Venetoclax (70-400mg)
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Los Angeles, California • North Haven, Connecticut • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

NCT00943501
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
14
States / cities
Cypress, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 17, 2026, 11:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228
View directory record Official record
Conditions
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
Interventions
VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
Drug
Lead sponsor
VM Oncology, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
14
States / cities
Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 17, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

NCT03893565
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GSK2831781 - Double Blind Phase, Placebo, GSK2831781 - Open Label phase
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Northridge, California • Rialto, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 17, 2026, 11:03 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint

NCT01123486
View directory record Official record
Conditions
Pain, Ventilatory Depression
Interventions
hydromorphone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

NCT06686797
View directory record Official record
Conditions
Healthy
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Phase 2a Study of VTX3232 in Parkinson's Disease

NCT06556173
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
VTX3232
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 17, 2026, 11:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Mirdametinib + BGB-3245 in Advanced Solid Tumors

NCT05580770
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Mirdametinib 2mg, BGB-3245 5mg, Mirdametinib 3mg, Mirdametinib 4mg, BGB-3245 10mg, BGB-3245 20mg
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
La Jolla, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 17, 2026, 11:03 AM EDT
Suspended Phase 2 Interventional

A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

NCT01325740
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
STX107
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 17, 2026, 11:03 AM EDT